Enlivex Therapeutics Stock Current Valuation
| ENLV Stock | ILA 428.50 28.30 7.07% |
Valuation analysis of Enlivex Therapeutics helps investors to measure Enlivex Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Enlivex Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Enlivex Therapeutics is based on 3 months time horizon. Increasing Enlivex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enlivex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enlivex Stock. However, Enlivex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 428.5 | Real 375.31 | Hype 400.2 | Naive 441.51 |
The real value of Enlivex Stock, also known as its intrinsic value, is the underlying worth of Enlivex Therapeutics Company, which is reflected in its stock price. It is based on Enlivex Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Enlivex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Enlivex Therapeutics helps investors to forecast how Enlivex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enlivex Therapeutics more accurately as focusing exclusively on Enlivex Therapeutics' fundamentals will not take into account other important factors: Enlivex Therapeutics Company Current Valuation Analysis
Enlivex Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Enlivex Therapeutics Current Valuation | 147.66 M |
Most of Enlivex Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enlivex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Enlivex Therapeutics has a Current Valuation of 147.66 M. This is 98.97% lower than that of the Healthcare sector and 96.82% lower than that of the Biotechnology industry. The current valuation for all Israel stocks is 99.11% higher than that of the company.
Enlivex Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is currently under evaluation in current valuation category among its peers.
Enlivex Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 147.66 M | |||
| Shares Outstanding | 18.41 M | |||
| Shares Owned By Insiders | 12.19 % | |||
| Shares Owned By Institutions | 9.53 % | |||
| Price To Book | 1.23 X | |||
| EBITDA | (18.74 M) | |||
| Net Income | (14.47 M) | |||
| Cash And Equivalents | 90.6 M | |||
| Cash Per Share | 4.95 X | |||
| Total Debt | 615 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 20.29 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (17.54 M) | |||
| Earnings Per Share | (1.07) X | |||
| Number Of Employees | 71 | |||
| Beta | 0.61 | |||
| Market Capitalization | 273.23 M | |||
| Total Asset | 95.15 M | |||
| Net Asset | 95.15 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Enlivex Stock
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.